

Publications for David Bishop

2018

Bishop, D., Xu, N., Tse, B., O'Brien, T., Gottlieb, D., Dolnikov, A., Micklethwaite, K. (2018). PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts. *Molecular Therapy*, 26(8), 1883-1895. [More Information]

2017

Withers, B., Blyth, E., Clancy, L., Yong, A., Fraser, C., Burgess, J., Simms, R., Brown, R., Kliman, D., Dubosq, M., Bishop, D., Sutrave, G., Ma, C., Micklethwaite, K., Gottlieb, D., et al (2017). Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. *Blood Advances*, 1(24), 2193-2205. [More Information]

2015

Ramanayake, S., Bilmon, I., Bishop, D., Dubosq, M., Blyth, E., Clancy, L., Gottlieb, D., Micklethwaite, K. (2015). Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. *Cytotherapy*, 17(9), 1251-1267. [More Information]

2014

Bishop, D., Johnston, A., Kwan, J., Antonenas, V., Gottlieb, D. (2014). Haploidentical peripheral blood stem cell infusion in combination with chemotherapy for acute myeloid leukaemia in elderly patients. *Internal Medicine Journal*, 44(10), 1038-1040. [More Information]

2003

Turner, J., Nicholas, H., Bishop, D., Matthews, J., Crossley, P. (2003). The LIM protein FHL3 binds basic Kruppel-like factor/Kruppel-like factor 3 and its co-repressor C-terminal-binding protein 2. *Journal of Biological Chemistry*, 278(15), 12786-12795. [More Information]